Financial Statements · From SEC 10-K & 10-Q XBRL Filings
Eli Lilly and Company Revenue & Financial Statements
Eli Lilly and Company reported revenue of $65.2B for the fiscal year ended December 31, 2025, up 44.7% year over year, with net income of $20.6B and diluted EPS of $22.95.
- Company
- Eli Lilly and Company LLY · NYSE
- Latest fiscal year
- FY ended Dec 31, 2025
- Statements
- Income · Balance Sheet · Cash Flow — 5 fiscal years, 8 quarters
Income Statement
Annual, as reported in 10-K filings. Values in USD.
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | 28.3B | 28.5B | 34.1B | 45.0B | 65.2B |
| Cost of revenue | 7.3B | 6.6B | 7.1B | 8.4B | 11.1B |
| Gross profit | 21.0B | 21.9B | 27.0B | 36.6B | 54.1B |
| Operating income | — | — | — | — | — |
| Pretax income | 6.2B | 6.8B | 6.6B | 12.7B | 25.7B |
| Net income | 5.6B | 6.2B | 5.2B | 10.6B | 20.6B |
| Diluted EPS | 6.12 | 6.90 | 5.80 | 11.71 | 22.95 |
| EBITDA | — | — | — | — | — |
Quarterly
| USD | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 8.8B | 11.3B | 11.4B | 13.5B | 12.7B | 15.6B | 17.6B | 19.3B |
| Cost of revenue | 1.7B | 2.2B | 2.2B | 2.4B | 2.2B | 2.4B | 3.0B | 3.4B |
| Gross profit | 7.1B | 9.1B | 9.3B | 11.1B | 10.5B | 13.1B | 14.6B | 15.9B |
| Operating income | — | — | — | — | — | — | — | — |
| Pretax income | 2.5B | 3.5B | 1.6B | 5.0B | 3.5B | 6.8B | 7.2B | 8.3B |
| Net income | 2.2B | 3.0B | 970.3M | 4.4B | 2.8B | 5.7B | 5.6B | 6.6B |
| Diluted EPS | 2.48 | 3.28 | 1.07 | 4.88 | 3.06 | 6.29 | 6.21 | 7.39 |
| EBITDA | — | — | — | — | — | — | — | — |
Balance Sheet
Fiscal year-end snapshots. Values in USD.
| USD | FY2024 | FY2024 | FY2025 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| Total assets | — | 78.7B | — | 112.5B | — |
| Current assets | — | 32.7B | — | 55.6B | — |
| Cash & equivalents | — | 3.3B | — | 7.3B | — |
| Total liabilities | — | — | — | — | — |
| Current liabilities | — | 28.4B | — | 35.2B | — |
| Long-term debt | — | 28.5B | — | 40.9B | — |
| Total debt | — | 28.5B | — | 40.9B | — |
| Stockholders’ equity | — | 14.2B | — | 26.5B | — |
| Net debt | — | 25.3B | — | 33.6B | — |
Cash Flow Statement
Annual, as reported in 10-K filings. Values in USD.
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Operating cash flow | 7.3B | 7.1B | 4.2B | 8.8B | 16.8B |
| Investing cash flow | (2.8B) | (3.3B) | (7.2B) | (9.3B) | (11.0B) |
| Financing cash flow | (4.1B) | (5.4B) | 3.5B | 1.2B | (2.2B) |
| Capital expenditure | — | — | — | — | — |
| Free cash flow | — | — | — | — | — |
| Dividends paid | 3.1B | 3.5B | 4.1B | 4.7B | 5.4B |
| Stock-based compensation | 342.8M | 371.1M | 628.5M | 645.6M | 626.0M |
Figures are parsed from SEC XBRL company facts and may be derived where issuers report year-to-date values (quarterly figures differenced; Q4 computed as FY minus Q3). Fiscal periods follow each company's fiscal calendar, not calendar years. Historical fact, not investment advice — verify with official SEC filings.
Every LLY filing, connected
Financials beside price, insider trades, and 8-K events — with alerts the moment something new is filed.